[go: up one dir, main page]

RU2000116633A - Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция - Google Patents

Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция

Info

Publication number
RU2000116633A
RU2000116633A RU2000116633/04A RU2000116633A RU2000116633A RU 2000116633 A RU2000116633 A RU 2000116633A RU 2000116633/04 A RU2000116633/04 A RU 2000116633/04A RU 2000116633 A RU2000116633 A RU 2000116633A RU 2000116633 A RU2000116633 A RU 2000116633A
Authority
RU
Russia
Prior art keywords
pharnesyl
transferase
producing
respect
pharmaceutical composition
Prior art date
Application number
RU2000116633/04A
Other languages
English (en)
Other versions
RU2179975C1 (ru
Inventor
Хиун Ил ЛИ (KR)
Хиун Ил ЛИ
Дзонг Сунг КОХ (KR)
Дзонг Сунг Кох
Дзин Хо ЛИ (KR)
Дзин Хо ЛИ
Вон Хи ДЗУНГ (KR)
Вон Хи ДЗУНГ
Ю Сеунг ШИН (KR)
Ю Сеунг ШИН
Хиун Хо ЧУНГ (KR)
Хиун Хо ЧУНГ
Дзонг Хиун КИМ (KR)
Дзонг Хиун КИМ
Сеонг Гу РО (KR)
Сеонг Гу РО
Тае Саенг ЧОЙ (KR)
Тае Саенг ЧОЙ
Шин Ву ДЗЕОНГ (KR)
Шин Ву ДЗЕОНГ
Тае Хван КВАК (KR)
Тае Хван КВАК
Ин Ае АХН (KR)
Ин Ае Ахн
Хиун Сунг КИМ (KR)
Хиун Сунг КИМ
Сун Хва ЛИ (KR)
Сун Хва ЛИ
Кви Хва КИМ (KR)
Кви Хва КИМ
Дзунг Квон ЙОО (KR)
Дзунг Квон ЙОО
Original Assignee
Эл Джи Кемикал Лтд. (KR)
Эл Джи Кемикал Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980011359A external-priority patent/KR19990066679A/ko
Priority claimed from KR1019980023698A external-priority patent/KR20000002788A/ko
Priority claimed from KR1019980046457A external-priority patent/KR20000015758A/ko
Application filed by Эл Джи Кемикал Лтд. (KR), Эл Джи Кемикал Лтд. filed Critical Эл Джи Кемикал Лтд. (KR)
Application granted granted Critical
Publication of RU2179975C1 publication Critical patent/RU2179975C1/ru
Publication of RU2000116633A publication Critical patent/RU2000116633A/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Claims (1)

  1. Текст формулы в факсимильном виде (см. графическую часть).
RU2000116633/04A 1997-11-28 1998-11-25 Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, способ их получения, промежуточные соединения, фармацевтическая композиция RU2179975C1 (ru)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
KR1997/63858 1997-11-28
KR19970063858 1997-11-28
KR1998/11359 1998-03-31
KR1019980011359A KR19990066679A (ko) 1997-11-28 1998-03-31 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR1019980023698A KR20000002788A (ko) 1998-06-23 1998-06-23 피라졸 구조를 갖는 파네실 전이효소 억제제 및그의 제조방법
KR1998/23698 1998-06-23
KR1019980024423A KR19990062439A (ko) 1997-11-28 1998-06-26 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR1998/24423 1998-06-26
KR19980031512 1998-08-03
KR1998/31512 1998-08-03
KR1998/46457 1998-10-30
KR1019980046457A KR20000015758A (ko) 1998-08-03 1998-10-30 피롤 구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법

Publications (2)

Publication Number Publication Date
RU2179975C1 RU2179975C1 (ru) 2002-02-27
RU2000116633A true RU2000116633A (ru) 2004-02-20

Family

ID=27555104

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000116633/04A RU2179975C1 (ru) 1997-11-28 1998-11-25 Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, способ их получения, промежуточные соединения, фармацевтическая композиция

Country Status (18)

Country Link
US (3) US6268363B1 (ru)
EP (1) EP1045846B1 (ru)
JP (2) JP3548118B2 (ru)
CN (1) CN1188407C (ru)
AR (1) AR017700A1 (ru)
AT (1) ATE239014T1 (ru)
AU (1) AU731272B2 (ru)
BR (1) BR9815423A (ru)
CA (1) CA2310629A1 (ru)
DE (1) DE69814167T2 (ru)
ES (1) ES2193590T3 (ru)
HU (1) HUP0004238A3 (ru)
ID (1) ID24175A (ru)
IL (1) IL135473A0 (ru)
NZ (1) NZ504013A (ru)
PL (1) PL340729A1 (ru)
RU (1) RU2179975C1 (ru)
WO (1) WO1999028315A1 (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745855B2 (en) * 1998-02-02 2002-04-11 Lg Chemical Ltd. Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
KR100395300B1 (ko) * 1999-08-11 2003-08-27 주식회사 엘지생명과학 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
US6511978B1 (en) * 1999-04-13 2003-01-28 Lg Life Sciences, Ltd. Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
KR100412334B1 (ko) * 2000-02-22 2003-12-31 주식회사 엘지생명과학 4-치환된-1ｈ-피롤-3-카복실산 에스테르의 새로운 제조방법
WO2001074807A1 (en) * 2000-03-30 2001-10-11 Sagami Chemical Research Center Indolylpyrrole derivatives and cell death inhibitors
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
RU2462463C2 (ru) * 2002-08-23 2012-09-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4585448B2 (ja) * 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 第Ｘａ因子阻害剤としてのピラゾール−誘導体
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
WO2005007631A1 (en) * 2003-07-10 2005-01-27 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome p450 inhibitors
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US7214825B2 (en) 2003-10-17 2007-05-08 Honeywell International Inc. O-(3-chloropropenyl) hydroxylamine free base
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
WO2005116001A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
EP2051977A2 (en) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
EP2906598A1 (en) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
SG11201509982UA (ru) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3154583T (pt) 2014-06-04 2021-03-24 Biontech Res And Development Inc Anticorpos monoclonais humanos para o gangliósido gd2
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
EP3519392A1 (en) 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazole derivatives
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20250139417A (ko) 2017-05-31 2025-09-23 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5681795A (en) * 1994-03-02 1997-10-28 Zeneca Limited 3-benzoyl pyrrole and pyrazole herbicides
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250919C (en) * 1996-03-29 2008-05-13 Therakos, Inc. Photopheresis treatment of leukocytes
WO1997036901A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036876A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249650A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507956A (ja) * 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤
CA2249617A1 (en) * 1996-04-03 1997-10-09 S. Jane Desolms Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
US6472526B1 (en) 2002-10-29
EP1045846B1 (en) 2003-05-02
JP3548118B2 (ja) 2004-07-28
IL135473A0 (en) 2001-05-20
HUP0004238A3 (en) 2001-07-30
US20020137769A1 (en) 2002-09-26
DE69814167T2 (de) 2004-02-26
HUP0004238A2 (hu) 2001-05-28
NZ504013A (en) 2002-02-01
DE69814167D1 (de) 2003-06-05
AR017700A1 (es) 2001-09-12
EP1045846A1 (en) 2000-10-25
AU731272B2 (en) 2001-03-29
ATE239014T1 (de) 2003-05-15
CN1188407C (zh) 2005-02-09
ID24175A (id) 2000-07-13
CA2310629A1 (en) 1999-06-10
BR9815423A (pt) 2000-10-17
PL340729A1 (en) 2001-02-26
RU2179975C1 (ru) 2002-02-27
JP2001524550A (ja) 2001-12-04
US6518429B2 (en) 2003-02-11
ES2193590T3 (es) 2003-11-01
JP2002161092A (ja) 2002-06-04
WO1999028315A1 (en) 1999-06-10
AU1508399A (en) 1999-06-16
CN1279680A (zh) 2001-01-10
US6268363B1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
RU2000116633A (ru) Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция
RU2002112227A (ru) Производные пятичленных гетероциклов, способ их получения и их применение в качестве лекарственных средств
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
BG103805A (en) Trifluoromethylalkylaminotriazolopyrimidines with fungicidal effect
RU2002120504A (ru) Трифторметилпирролкарбоксамиды и трифторметилпирролтиоамиды в качестве фунгицидов
ZA985456B (en) Solid pharmaceutical composition containing benzofuran derivatives.
FI964285L (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
HUP0202520A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
DE60025385D1 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
PL320916A1 (en) Derivatives of piperasino 2,5-dione as modulators of drug-fastness in respect to amny drugs
FR2681067B1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
HUP0202701A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
NO904901D0 (no) N-substituerte derivater av 3r,4r-etyl-((1-metyl-1h-imidazol-5-yl)metyl) -2-pyrrolidinon.
ZA93821B (en) New derivatives of baccatin III and of 10-deacetyibaccatin III, their preparation and the pharmaceutical compositions which contain them.
CA2153549A1 (fr) Nouveau derive de benzothiadiazine, son procede de preparation et les compositions pharmeceutiques qui le contiennent
FI970448L (fi) N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat käyttökelpoisia neuroleptisina aineina
AP9801377A0 (en) Tricyclic erythromycin derivatives.
BG103735A (en) Method for the preparation of substituted thiazolidindions

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061126